Form 4: Oramed CEO Sells Shares for Tax Obligations

Oramed Pharmaceuticals CEO Nadav Kidron disposed of 44,818 shares of common stock to cover tax withholding obligations related to RSU vesting.

Summary

• Nadav Kidron, President and CEO, Director, and 10% Owner of Oramed Pharmaceuticals Inc. (ORMP), reported a transaction on March 30, 2026.
• The transaction involved the disposal of 44,818 shares of common stock.
• These shares were used to satisfy tax withholding obligations arising from the vesting and settlement of Restricted Stock Units (RSUs).
• The shares were valued at $3.31 per share, which was the closing price on the day immediately prior to the vesting date.
• Following this transaction, Nadav Kidron directly beneficially owns 3,422,243 shares of common stock.
• Additionally, 126,000 shares are indirectly beneficially owned through a wholly-owned corporation.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event. It is a standard, non-discretionary transaction related to executive compensation and tax management, providing no new insights into the company's operational or financial performance.

Industry Context

StockSavvy.ai notes that the disposal of shares to cover tax withholding obligations upon the vesting of Restricted Stock Units (RSUs) is a common and routine practice for executives receiving equity compensation across various industries. This type of transaction is typically non-discretionary and pre-planned, often through a Rule 10b5-1 plan, to manage tax liabilities associated with equity awards.

Comparison to Industry Standards

• This transaction aligns with standard industry practices for executive compensation and tax management. Many public company executives utilize 'sell-to-cover' strategies for RSU vesting, similar to practices observed at companies like Pfizer (PFE), Johnson & Johnson (JNJ), and Merck (MRK) where executives frequently report such disposals in their Form 4 filings.

Stakeholder Impact

• Shareholders: Minimal direct impact as this is a routine, non-discretionary transaction for tax purposes and does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact mentioned.

Key Dates

Recommendation

This Form 4 filing details a routine insider transaction where the CEO sold shares to cover tax obligations from RSU vesting. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The transaction is a standard practice and does not indicate a change in management's confidence in the company's long-term prospects, thus a 'hold' recommendation is maintained based solely on this filing.

Keywords

Oramed Pharmaceuticals, ORMP, Nadav Kidron, Form 4, Insider Transaction, Restricted Stock Units, Tax Withholding, Equity Compensation